In DLBCL, the frequency of Bcl-2-positive cases is highly variable, ranging from 24% to 80% in examined specimens in the previous studies that used IHC; so, its predictive relevance to the first-line treatment is considered controversial [36]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.